Bristol-Myers Squibb (NYSE:BMY) Stock Price Up 0.2%

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) shares shot up 0.2% during mid-day trading on Tuesday . The stock traded as high as $49.47 and last traded at $49.25. 1,272,055 shares were traded during mid-day trading, a decline of 92% from the average session volume of 15,421,163 shares. The stock had previously closed at $49.14.

Analyst Upgrades and Downgrades

Several analysts have commented on BMY shares. William Blair restated a "market perform" rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday, April 15th. Bank of America downgraded Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their price target for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Societe Generale cut Bristol-Myers Squibb from a "buy" rating to a "hold" rating in a research report on Monday, March 11th. Finally, Redburn Atlantic lowered Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their target price for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $61.18.

Bristol-Myers Squibb Stock Down 0.3 %

The stock's fifty day simple moving average is $51.22 and its 200-day simple moving average is $51.32. The stock has a market cap of $99.31 billion, a P/E ratio of 12.69, a P/E/G ratio of 1.48 and a beta of 0.39. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.31 and a current ratio of 1.43.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.55 by $0.15. The firm had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The company's revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.82 EPS. As a group, research analysts forecast that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 dividend on an annualized basis and a yield of 4.90%. Bristol-Myers Squibb's dividend payout ratio (DPR) is currently 62.18%.

Institutional Trading of Bristol-Myers Squibb

Several large investors have recently modified their holdings of BMY. Riversedge Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 3.2% during the third quarter. Riversedge Advisors LLC now owns 5,691 shares of the biopharmaceutical company's stock valued at $330,000 after purchasing an additional 178 shares during the period. Vicus Capital grew its stake in Bristol-Myers Squibb by 3.9% in the third quarter. Vicus Capital now owns 4,824 shares of the biopharmaceutical company's stock valued at $280,000 after acquiring an additional 179 shares during the period. Lindbrook Capital LLC raised its position in shares of Bristol-Myers Squibb by 2.3% during the third quarter. Lindbrook Capital LLC now owns 8,060 shares of the biopharmaceutical company's stock worth $468,000 after purchasing an additional 182 shares during the period. Addison Advisors LLC lifted its holdings in shares of Bristol-Myers Squibb by 6.6% in the 3rd quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 192 shares in the last quarter. Finally, Symphony Financial Ltd. Co. increased its stake in Bristol-Myers Squibb by 4.1% during the 3rd quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company's stock valued at $288,000 after purchasing an additional 194 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.